biotechnology

Cleavage of xanthone and flavone C–glycosidic bonds by the enzyme complex LaGME from gut Lachnospiraceae

October 30, 2026

Aglycones, the bioactive metabolites of C–glycosides, can be obtained through the deglycosylation of naturally abundant C–glycosides. However, C–glycosides…

HHealthcare

Novartis remibrutinib MS drug faces efficacy questions

October 30, 2026

“This medicine could be one of our largest medicines in history,” Novartis CEO Vas Narasimhan told CNBC on…

HHealthcare

October 29, 2026

Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales…

MMedication

Launch price of new medicines dropped very slightly in 2025

October 20, 2026

Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly…

MMedication

October 15, 2026

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…

HHealthcare

UnitedHealth Group (UNH) earnings Q3 2026

October 13, 2026

UnitedHealth Group signage on the floor of the New York Stock Exchange on April 21, 2025. Michael Nagle…

NNutrition

Supplement sector rising, ‘safety needs to evolve with it’

October 13, 2026

Speaking during a webinar hosted by the International Alliance of Dietary and Food Supplement Associations (IADSA) last week,…

NNutrition

USFDA’s gummy study, Australia’s rules on andrographis in regulatory round-up

October 9, 2026

The mature dietary supplement market has been drawing increasing scrutiny from regulators, inspectors and legacy supplement brands. (Colorsandia…

MMedication

Probing the many benefits of GLP-1 receptor agonists

October 6, 2026

RESEARCH HIGHLIGHT 05 October 2026 Glucagon-like peptide 1 (GLP-1) receptor agonists are approved for the treatment of type…

HHealthcare

October 3, 2026

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…

HHealth

COVID-19 immunity shows cross-reactivity against related bat coronaviruses

October 2, 2026

People who recovered from COVID-19 infection or were vaccinated against SARS-CoV-2 are more likely to have immunity to…

MMedication

September 30, 2026

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6…

Cleavage of xanthone and flavone C–glycosidic bonds by the enzyme complex LaGME from gut Lachnospiraceae

Novartis remibrutinib MS drug faces efficacy questions

Eli Lilly (LLY) earnings Q3 2026

Launch price of new medicines dropped very slightly in 2025

New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year

UnitedHealth Group (UNH) earnings Q3 2026

Supplement sector rising, ‘safety needs to evolve with it’

USFDA’s gummy study, Australia’s rules on andrographis in regulatory round-up

Probing the many benefits of GLP-1 receptor agonists

Eli Lilly, NIH grants, Novartis, Regeneron: Readout Newsletter

COVID-19 immunity shows cross-reactivity against related bat coronaviruses

Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes